IQVIA Holdings Inc. (IQV) had an impressive run in the past three months. The company's shares have gained 12.5% compared with the 3.4% rally of its industry and the 2.5% rise of the Zacks S&P 500 composite. IQV reported impressive second-quarter 2024 results. Adjusted earnings (excluding 67 cents from nonrecurring items) were $2.6 per share, outpacing the Zacks Consensus Estimate by 2.3% and increasing 2.4% on a year-over-year basis. Total revenues of $3.8 billion surpassed the consensus estimate marginall ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

文章核心观点 - IQVIA是全球最大的合同研究组织,其最大的差异化在于其数据资产 [1] - 过去2.5年,IQVIA的投资者情绪和每股收益增长受到了新冠疫情、利息费用上升、生物制药融资环境恶化以及需求疲软等持续性挑战的严重影响 [1] - 由于上述因素,IQVIA的股价自2022年第一季度以来已经相对标普500指数下跌了约26% [1] - IQVIA拥有业内最大的医疗健康数据收集,为药物开发中的人工智能和数据机会提供最佳曝光 [1] 公司概况 - IQVIA管理着超过61PB的数据和超过12亿患者记录,来自15万多家数据供应商 [2] - 2023年,生物制药公司在外包临床药物开发方面的支出约为500亿美元,IQVIA的相关收入为84亿美元,市场渗透率约为17% [2] - IQVIA还估计在其他业务领域还有1500亿美元的支出机会,目前的市场渗透率为4-5% [2] 行业趋势 - 生物技术融资在2023年第一季度出现显著加速,这是一个长期指标,也影响了IQVIA约25%的研发订单 [3] - 分析师模型显示,行业研发支出将在2025年前呈上升趋势,这是一个短期指标 [3] - 2024年三期和四期临床试验有所增加,反映了当前的趋势 [3] - 2023年FDA新药和生物制品许可申请批准数量有显著上升 [3]

PHILADELPHIA, Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. IQVIA One Home for Sites is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solu ...

It has been about a month since the last earnings report for IQVIA Holdings (IQV) . Shares have added about 3.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is IQVIA due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. IQVIA Surpasses Q2 Earnings Estimates IQVIA Holdin ...

I I F ■ F Matteo Colombo Investment update Following my May publication on IQVIA Holdings Inc. (NYSE:IQV) the stock is +5%, marking a 28% return since I first rated the business investment-grade back in Jan '21. This is a business I know tremendously well, having analyzed its credentials for more than 3 years and owned the stock for our equity budget for that entire duration. In the five publications I've made on IQV here on SA since then, my views have not changed on this long-term compounder. Following it ...

Shares of IQVIA Holdings Inc. (IQV) have risen 12% over the past year, outperforming the 10% growth of the industry it belongs to. Image Source: Zacks Investment Research The company has an expected long-term (three to five years) EPS growth rate of 10.4%. Its earnings for 2024 and 2025 are anticipated to grow 9.5% and 11%, respectively, year over year. Factors That Bode Well IQVIA's top line is bolstered by the strong segmental performance.The Technology & Analytics Solutions ("TAS") segment delivered a 4% ...

Have you looked into how IQVIA Holdings (IQV) performed internationally during the quarter ending June 2024? Considering the widespread global presence of this clinical testing company, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must und ...

文章核心观点 - 文章比较了两家医疗器械公司IQVIA Holdings(IQV)和Waters(WAT)的估值指标,认为IQV目前更具有投资价值[3][6][7] - IQV的估值指标如市盈率、市销率等更具吸引力,而WAT的估值指标相对较高[6][7] - IQV的盈利预测修正活动更为积极,分析师对其前景评价更为乐观[3] 公司和行业概况 - IQVIA Holdings和Waters都是医疗器械行业的上市公司[1] - 投资者通常会关注这两家公司的股票[1] - 寻找估值合理的价值股是投资者的重点[2][4] - 估值指标如市盈率、市销率等是判断公司估值水平的重要依据[5][6][7]